Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 59,824	$ 65,064
Short-term marketable securities (amortized cost of $232,238 and $281,122, respectively)	232,056	281,337
Accounts receivable, net	35,610	37,969
Inventory	13,214	14,448
Prepaid expenses and other current assets	10,848	11,370
Total current assets	351,552	410,188
Long-term assets
Property and equipment, net	55,418	68,227
Operating lease right-of-use assets	48,521	52,096
Restricted cash	2,976	2,932
Intangible assets, net	4,281	5,128
Goodwill	118,972	118,972
Other assets	3,152	3,591
Total assets	584,872	661,134
Current liabilities
Accounts payable	9,867	7,719
Accrued liabilities	6,709	8,597
Accrued compensation and benefits	9,519	13,685
Current portion of operating lease liabilities	9,806	9,384
Current portion of deferred revenue	52,225	48,630
Total current liabilities	88,126	88,015
Long-term liabilities
Operating lease liabilities, less current portion	84,370	89,388
Deferred revenue, less current portion	38,844	44,793
Revenue interest liability, net	132,082	130,660
Other long-term liabilities	20
Total liabilities	343,442	352,856
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2024 and December 31, 2023; 147,462,201 and 145,082,271 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	14	14
Additional paid-in capital	1,479,832	1,452,502
Accumulated other comprehensive (loss) gain	(182)	215
Accumulated deficit	(1,238,061)	(1,144,332)
Total Adaptive Biotechnologies Corporation shareholders’ equity	241,603	308,399
Noncontrolling interest	(173)	(121)
Total shareholders’ equity	241,430	308,278
Total liabilities and shareholders’ equity	$ 584,872	$ 661,134